FIB-4 Index Calculator

FIB-4 is recommended as the initial screening test for advanced fibrosis in all adults with suspected chronic liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), chronic hepatitis B, chronic hepatitis C, and alcoholic liver disease. It requires only routine blood tests — a full blood count and liver function panel — making it universally available without additional cost.

Patients scoring < 1.30 (or < 2.0 if aged ≥ 65) can be managed in primary care with lifestyle modification, treatment of the underlying aetiology, and serial FIB-4 reassessment every 1–3 years. This pathway avoids unnecessary specialist referrals in the majority of patients and allows hepatology resources to be directed toward higher-risk individuals.

Patients with FIB-4 values in the indeterminate zone (1.30–2.67, or 2.0–2.67 if aged ≥ 65) require a second-line non-invasive test to refine risk stratification. The two main options are vibration-controlled transient elastography (VCTE, or FibroScan) and serum biomarker panels such as the Enhanced Liver Fibrosis (ELF) test or FibroTest.

VCTE measures liver stiffness in kilopascals (kPa). A liver stiffness measurement < 8 kPa generally excludes advanced fibrosis, while values > 12–15 kPa suggest F3–F4 disease. Combining FIB-4 with elastography in a sequential pathway substantially improves diagnostic accuracy compared to either test alone, increasing the area under the receiver-operating-characteristic curve (AUROC) to approximately 0.85–0.90 for advanced fibrosis detection.

Patients with a high-risk FIB-4 (> 2.67) or persistently elevated second-line results should be referred to hepatology for comprehensive evaluation. This may include further imaging (ultrasound, CT, or MRI for hepatocellular carcinoma screening), endoscopy for variceal assessment, and consideration of liver biopsy for definitive staging and aetiological evaluation.

Liver biopsy remains the reference standard for fibrosis staging but is invasive, carries a small risk of complications (bleeding, pain, organ injury), and is subject to sampling variability. Current guidelines reserve biopsy for cases where non-invasive tests are discordant, when an alternative or coexistent pathology is suspected, or when histological confirmation would meaningfully change management — for example, prior to initiating certain therapies or for transplant evaluation.

Several non-invasive fibrosis scores exist alongside FIB-4. The NAFLD Fibrosis Score (NFS) uses six variables (age, BMI, diabetes status, AST/ALT ratio, albumin, platelet count) and has similar diagnostic accuracy. The APRI (AST-to-Platelet Ratio Index) is simpler but less accurate. The ELF test uses three direct fibrosis biomarkers (hyaluronic acid, PIIINP, TIMP-1) and offers good performance but requires a specialised assay not available everywhere.

FIB-4 is preferred over NFS in most guideline pathways because it uses fewer variables, does not require BMI or diabetes status, and performs equally well or better in head-to-head comparisons. For MASLD specifically, the AGA 2023 guidance and EASL 2024 guidelines both endorse FIB-4 as the preferred first-line screening tool, with elastography or ELF as the recommended second-line test.

This is the single most common error. FIB-4 is designed to estimate chronic fibrosis, not to reflect acute liver injury. An AST of 500 U/L during an acute hepatitis B flare or a drug reaction will produce a dramatically elevated FIB-4 that bears no relationship to the underlying fibrosis stage. The result may suggest advanced fibrosis when the liver architecture is structurally intact.

Always verify that transaminases are at or near their baseline before calculating. If the patient is recovering from an acute event, wait until ALT and AST have stabilised (typically 4–8 weeks post-event) before applying FIB-4. As a practical check: if AST or ALT exceeds 5–10 times the upper limit of normal, the FIB-4 result is unreliable.

Because age is directly in the numerator, a healthy 70-year-old with completely normal liver function tests will produce a higher FIB-4 than an identical 40-year-old. Using the standard < 1.30 cutoff in elderly populations results in an unacceptably high rate of indeterminate results (up to 60–70% in some studies), leading to unnecessary specialist referrals and further testing.

The age-adjusted < 2.0 cutoff for patients ≥ 65 significantly reduces this over-referral problem. If your clinical pathway does not yet incorporate age-adjusted thresholds, consider discussing this with your hepatology team — the evidence supporting this adjustment is robust and endorsed by both AGA and EASL guidance.

FIB-4 is a screening tool with a high negative predictive value — it is best at ruling out advanced fibrosis, not ruling it in. A FIB-4 > 2.67 suggests high risk but has a positive predictive value of only approximately 65–80%, meaning that 20–35% of patients above this threshold may not actually have advanced fibrosis on biopsy. Similarly, FIB-4 cannot distinguish between F3 and F4, nor can it assess inflammatory activity or steatosis grade.

Avoid making definitive management decisions (e.g., diagnosing cirrhosis, starting specific treatments, or discussing transplant) based on FIB-4 alone. A high FIB-4 should trigger further investigation — not be treated as a final answer.

Each FIB-4 component can be influenced by non-hepatic conditions. Platelet count may be reduced by haematological disorders (ITP, myelodysplastic syndromes, bone marrow suppression from chemotherapy) or medications (heparin-induced thrombocytopaenia), falsely elevating FIB-4. Conversely, reactive thrombocytosis from infection or inflammation can mask portal hypertension-related thrombocytopaenia and falsely lower the score.

AST is not liver-specific — it is also released from skeletal muscle, cardiac muscle, and red blood cells. Strenuous exercise, rhabdomyolysis, haemolysis, and myocardial injury can all raise AST without hepatic involvement. If a patient has an unexpectedly elevated FIB-4 and a possible non-hepatic source of AST elevation, consider checking a CK level or assessing for haemolysis before attributing the result to liver fibrosis.

A single FIB-4 value is a snapshot, not a trajectory. Fibrosis is a dynamic process — it can progress with ongoing liver injury or regress with effective treatment (e.g., viral eradication in hepatitis C, sustained abstinence in alcohol-related liver disease, weight loss in MASLD). Guidelines recommend serial FIB-4 measurement every 1–3 years in at-risk patients, particularly those with metabolic risk factors or ongoing exposure to hepatotoxins.

A rising FIB-4 trend over time — even if the absolute value remains below the high-risk threshold — may indicate progressive fibrosis and should prompt closer evaluation. Conversely, a declining trend after treatment (e.g., post-SVR in hepatitis C) is reassuring and may allow de-escalation of surveillance.